[Response to S-1+paclitaxel in far-advanced gastric cancer].

The patient was a 55-year-old man who was treated with S-1 and paclitaxel(PTX)combination chemotherapy for inoperable advanced gastric cancer in whom an abdominal CT examination had revealed peritoneal dissemination, pancreatic invasion, and ascites. A total of 15 courses of S-1 120 mg/day for 2 weeks followed by a 2-week rest period and PTX 90 mg/ body on day 1, 8, and 15 were administered. The CT examination after the completion of chemotherapy showed resolution of the ascites, and no evidence of peritoneal dissemination was observed on the images.

Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.

Purpose: The effect of gastrectomy on pharmacokinetics after S-1 administration was investigated.

Patients And Methods: A dose of 40 mg/m(2) of S-1 was administered orally twice daily for 7 days (80 mg/m(2)/day) preoperatively in ten patients with resectable gastric cancer, and the same dose of S-1 was administered for 28 consecutive days after gastrectomy. Plasma concentrations of tegafur, gimeracil, and oteracil potassium, all the components of S-1, and 5-FU were measured on pre- and postoperative days.

Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer.

BACKGROUND: This clinicopathological study evaluated the utility of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 as predictors of locoregional recurrence and long-term disease-free survival in patients with gastric cancer.METHODS: During the period January 1989 to December 1994, 485 patients with primary gastric cancer were evaluated. Gastrectomies were performed in 434 patients.